REGENXBIO Inc. — clemidsogene lanparvovec (RGX-121) - (CAMPSI · MPS II (Hunter Syndrome).
Run-up into the decision (T-120 → T+5)
Daily close, T-120 (8/25/25) through T+5. Run-up high $15.98 on 1/22/26, low $8.03 on 8/26/25 (T-120 to T-1). FDA decision 2/9/26. Historical price action, not a forecast.
Key facts
FDA decision date2026-02-09
OutcomeCRL
Drug / candidateclemidsogene lanparvovec (RGX-121) - (CAMPSI